• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Deutsche Bank's Depositary Receipts Virtual Investor Conference presentations now available for on-demand viewing

    11/19/21 10:59:00 AM ET
    $AIH
    $AZN
    $BLCT
    $BTCM
    Medical Specialities
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AIH alert in real time by email

    NEW YORK, Nov. 19, 2021 /CNW/ - Deutsche Bank today announced that the presentations from the November 16th and 17th  Depositary Receipts Virtual Investor Conference ("dbVIC") are now available for on-demand viewing. The event featured presentations from international companies with American Depositary Receipt (ADR) programs in the US.

    Representatives from participating companies based in Australia, China, Germany, France and the UK presented their equity stories and answered audience questions. The presentations are targeted to all types of investors as well as analysts interested in non-US companies.

    To log in, please use the following link: www.adr.db.com/dbvic 

    The company presentations will be available 24/7 for 90 days. Investors, advisors and analysts may download shareholder materials from the "virtual trade booth" for the next three weeks.

    The following companies participated in the conference:

    • Hywin ((HYW)
    • First Pacific ((Hong Kong: 142_HK, OTC:FPAFY)
    • Telstra ((Australia: TLS, OTC:TLSYY)
    • BlueCity Holdings ((BLCT)
    • Yiren Digital ((YRD)
    • Ecofibre ((Australia: EOF, OTC:EOFBY)
    • Ipsen ((Paris: IPN, OTC:IPSEY)
    • Travis Perkins ((London: TPK, OTC:TPRKY)
    • HUTCHMED ((HCM, London: HCM))
    • China Online Education ((COE)
    • NIO ((NIO)
    • Aesthetic Medical International Holdings ((AIH)
    • Quhuo ((QH)
    • AstraZeneca ((London: AZN, NASDAQ:AZN)
    • BIT Mining ((BTCM)
    • Hugo Boss ((Germany: BOSS, OTC:BOSSY)

    In addition to specializing in administering cross-border equity structures such as American and Global Depositary Receipts, Deutsche Bank provides corporates, financial institutions, hedge funds and supranational agencies around the world with trustee, agency, escrow and related services. The Bank offers a broad range of services for diverse products, from complex securitizations and project finance to syndicated loans, debt exchanges and restructurings.

    Deutsche Bank provides commercial and investment banking, retail banking, transaction banking and asset and wealth management products and services to corporations, governments, institutional investors, small and medium-sized businesses, and private individuals. Deutsche Bank is Germany's leading bank, with a strong position in Europe and a significant presence in the Americas and Asia Pacific.

    Deutsche Bank is sponsoring the Deutsche Bank Depositary Receipt Investor Conference solely for informational purposes. Deutsche Bank does not prepare, review, approve or edit any presentations, statements, documents or other information or materials, whether in written, electronic or verbal form, provided by any company participating in such conference, and disclaims any responsibility for the accuracy or adequacy of any such information or materials. Deutsche Bank is not promoting, endorsing or recommending any company participating in the conference.

    The Depositary Receipts have been registered pursuant to the US Securities Act of 1933 (the "Act"). The investment or investment service which is the subject of this notice is not available to retail clients as defined by the UK Financial Conduct Authority. This notice has been approved and/or communicated by Deutsche Bank AG New York. The services described in this notice are provided by Deutsche Bank Trust Company Americas (Deutsche Bank) or by its subsidiaries and/or affiliates in accordance with appropriate local registration and regulation. Deutsche Bank is providing the attached notice strictly for information purposes and makes no claims or statement, nor does it warrant or in any way represent, as to the accuracy or completeness of the details contained herein or therein. This announcement appears as a matter of record only. Neither this announcement nor the information contained herein constitutes an offer or solicitation by Deutsche Bank or any other issuer or entity for the purchase or sale of any securities nor does it constitute a solicitation to any person in any jurisdiction where solicitation would be unlawful. No part of this notice may be copied or reproduced in any way without the prior written consent of Deutsche Bank. Past results are not an indication of future performance. Copyright© November 2021 Deutsche Bank AG. All rights reserved.

    SOURCE dbVIC - Deutsche Bank Depositary Receipts Virtual Investor Conference

    Cision View original content: http://www.newswire.ca/en/releases/archive/November2021/19/c6486.html

    Get the next $AIH alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AIH
    $AZN
    $BLCT
    $BTCM

    CompanyDatePrice TargetRatingAnalyst
    NIO Inc.
    $NIO
    9/23/2025$8.10 → $8.60Buy
    Citigroup
    HUTCHMED (China) Limited
    $HCM
    9/22/2025$13.75Equal-Weight → Underweight
    Morgan Stanley
    NIO Inc.
    $NIO
    9/16/2025$8.50Neutral → Buy
    UBS
    NIO Inc.
    $NIO
    8/26/2025$8.00Neutral → Overweight
    Analyst
    NIO Inc.
    $NIO
    8/1/2025$5.50Neutral → Outperform
    Macquarie
    NIO Inc.
    $NIO
    6/17/2025$3.70 → $3.80Sell → Neutral
    Goldman
    HUTCHMED (China) Limited
    $HCM
    5/13/2025Buy → Hold
    HSBC Securities
    AstraZeneca PLC
    $AZN
    4/15/2025$75.00Outperform
    Exane BNP Paribas
    More analyst ratings

    $AIH
    $AZN
    $BLCT
    $BTCM
    Leadership Updates

    Live Leadership Updates

    View All

    HUTCHMED Announces Appointment of Acting Chief Executive Officer

    HONG KONG and SHANGHAI and FLORHAM PARK, N.J, Aug. 25, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM:​HCM; HKEX:​13) today announces that Dr Weiguo Su, an Executive Director of the Company, will take a leave of absence from his duties as Chief Executive Officer due to health reasons. In light of this, the Board of Directors has appointed Mr Johnny Cheng, an Executive Director and Chief Financial Officer of the Company, as Acting Chief Executive Officer with immediate effect, in addition to his role as Chief Financial Officer. Dr Dan Eldar, Chairman and Non-executive Director, said, "The Board expresses its full support for Dr Su and wishes him a speedy recover

    8/24/25 8:20:00 PM ET
    $HCM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    51Talk Online Education Group to Present on the Emerging Growth Conference on June 17, 2025.

    51Talk Online Education Group invites individual and institutional investors as well as advisors and analysts, to attend its real-time, interactive presentation on the Emerging Growth Conference. SINGAPORE, June 12, 2025 /PRNewswire/ -- 51Talk Online Education Group (the "Company") (NYSE:COE), a global online education platform with core expertise in English education, is pleased to announce that it has been invited to present on the Emerging Growth Conference on June 17, 2025. The next Emerging Growth Conference is presenting on June 17, 2025. This live, interactive online event will give existing shareholders and the investment community the opportunity to interact with the Company's inve

    6/12/25 5:30:00 AM ET
    $COE
    Other Consumer Services
    Real Estate

    HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee

    HONG KONG and SHANGHAI and FLORHAM PARK, N.J., March 05, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited ("HUTCHMED" or the "Company") (Nasdaq/AIM:​HCM, HKEX:​13) today announces that Mr Wong Tak Wai (Mr Alvin Wong) is appointed as an Independent Non-executive Director and a member of the Audit Committee of the Company with effect from March 6, 2025. Mr Wong has over 35 years of extensive experience in accounting, auditing and corporate finance. He has acted in a pivotal role in assisting companies with their stock exchange listings and has been instrumental in completing numerous mergers and acquisitions. After a distinguished career spanning more than three decades, Mr Wong retired as

    3/5/25 5:00:00 AM ET
    $HCM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AIH
    $AZN
    $BLCT
    $BTCM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    ENHERTU® Followed by THP Supplemental Biologics License Application Accepted in the U.S. for Patients with High-Risk HER2 Positive Early-Stage Breast Cancer Prior to Surgery

    Based on results from DESTINY-Breast11, the first phase 3 trial to demonstrate benefit of Daiichi Sankyo and AstraZeneca's ENHERTU in early-stage breast cancer If approved, ENHERTU followed by THP could represent a new treatment approach prior to surgery in this setting Daiichi Sankyo (TSE: 4568) and AstraZeneca's (NASDAQ:AZN) supplemental Biologics License Application (sBLA) for ENHERTU® (fam-trastuzumab deruxtecan-nxki) followed by paclitaxel, trastuzumab and pertuzumab (THP) has been accepted for review in the U.S. for the neoadjuvant treatment of adult patients with HER2 positive (IHC 3+ or ISH+) stage 2 or stage 3 breast cancer. ENHERTU is a specifically engineered HER2 direct

    10/1/25 7:00:00 AM ET
    $AZN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NIO Inc. Provides September and Third Quarter 2025 Delivery Update

    Company Achieved New Record-High Monthly and Quarterly Deliveries 34,749 vehicles were delivered in September 2025, increasing by 64.1% year-over-year87,071 vehicles were delivered in the three months ended September 2025, increasing by 40.8% year-over-yearCumulative deliveries reached 872,785 as of September 30, 2025   SHANGHAI, Oct. 01, 2025 (GLOBE NEWSWIRE) -- NIO Inc. (NYSE:NIO, HKEX: 9866, SGX: NIO)) ("NIO" or the "Company"), a pioneer and a leading company in the global smart electric vehicle market, today announced its September and third quarter 2025 delivery results. The Company delivered 34,749 vehicles in September 2025, reaching a new monthly record and representing an incre

    10/1/25 3:45:00 AM ET
    $NIO
    Auto Manufacturing
    Industrials

    Quhuo's Hotel and Home Services Sector Partners with Beike to Improve Residential Service Quality

    BEIJING, Sept. 30, 2025 /PRNewswire/ -- Quhuo Limited (NASDAQ:QH) ("Quhuo" or the "Company"), a leading gig economy platform for local services in China, announced recently that its subsidiary, Lailai Information Technology (Shenzhen) Co., Ltd. ("Lailai"), which specializes in hotel and home services, has formed a partnership with Ke Holdings Inc. ("Beike"), a leading housing transactions and services platform in China. Under the agreement, Lailai will provide Beike with asset services including property maintenance before and after listing, ongoing household support, and tailored services for specific groups of residents. The collaboration expands Lailai's service scope from home services t

    9/30/25 8:00:00 AM ET
    $QH
    Real Estate

    $AIH
    $AZN
    $BLCT
    $BTCM
    SEC Filings

    View All

    SEC Form 6-K filed by AstraZeneca PLC

    6-K - ASTRAZENECA PLC (0000901832) (Filer)

    10/1/25 10:19:19 AM ET
    $AZN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by NIO Inc.

    6-K - NIO Inc. (0001736541) (Filer)

    10/1/25 6:04:05 AM ET
    $NIO
    Auto Manufacturing
    Industrials

    SEC Form 6-K filed by HUTCHMED (China) Limited

    6-K - HUTCHMED (China) Ltd (0001648257) (Filer)

    9/30/25 6:15:03 AM ET
    $HCM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AIH
    $AZN
    $BLCT
    $BTCM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Citigroup reiterated coverage on NIO with a new price target

    Citigroup reiterated coverage of NIO with a rating of Buy and set a new price target of $8.60 from $8.10 previously

    9/23/25 10:10:35 AM ET
    $NIO
    Auto Manufacturing
    Industrials

    HUTCHMED downgraded by Morgan Stanley with a new price target

    Morgan Stanley downgraded HUTCHMED from Equal-Weight to Underweight and set a new price target of $13.75

    9/22/25 8:24:03 AM ET
    $HCM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NIO upgraded by UBS with a new price target

    UBS upgraded NIO from Neutral to Buy and set a new price target of $8.50

    9/16/25 8:00:00 AM ET
    $NIO
    Auto Manufacturing
    Industrials

    $AIH
    $AZN
    $BLCT
    $BTCM
    Financials

    Live finance-specific insights

    View All

    51Talk Online Education Group Announces Second Quarter 2025 Results

    SINGAPORE, Sept. 3, 2025 /PRNewswire/ -- 51Talk Online Education Group ("51Talk" or the "Company") (NYSE American: COE), a global online education platform with core expertise in English education, announced its unaudited results for the second quarter ended June 30, 2025. Second Quarter 2025 Financial and Operating Highlights Gross billings[1] for the second quarter of 2025 were US$28.5 million, a 79.7% growth from US$15.9 for the second quarter of 2024.Net revenues for the second quarter of 2025 were US$20.4 million, an 86.1% increase from US$11.0 million for the second quarter of 2024.The number of quarterly active students with attended lesson consumption for the second quarter of 2025

    9/3/25 5:00:00 AM ET
    $COE
    Other Consumer Services
    Real Estate

    NIO Inc. Reports Unaudited Second Quarter 2025 Financial Results

    Quarterly Total Revenues Reached RMB19,008.7 million (US$2,653.5 million)iQuarterly Vehicle Deliveries were 72,056 units SHANGHAI, China, Sept. 02, 2025 (GLOBE NEWSWIRE) -- NIO Inc. (NYSE:NIO, HKEX: 9866, SGX: NIO)) ("NIO" or the "Company"), a pioneer and a leading company in the global smart electric vehicle market, today announced its unaudited financial results for the second quarter ended June 30, 2025. Operating Highlights for the Second Quarter of 2025 Vehicle deliveries were 72,056 in the second quarter of 2025, representing an increase of 25.6% from the second quarter of 2024, and an increase of 71.2% from the first quarter of 2025. The deliveries consisted of 47,132 vehicles fr

    9/2/25 5:30:42 AM ET
    $NIO
    Auto Manufacturing
    Industrials

    Baxdrostat demonstrated statistically significant and clinically meaningful reduction in systolic blood pressure in patients with hard-to-control hypertension in the BaxHTN Phase III ​trial

    Baxdrostat 2mg lowered systolic blood pressure by 15.7 mmHg (9.8 mmHg placebo-adjusted) from baseline, and was generally well tolerated with no unanticipated safety findings Full results presented at the European Society of Cardiology Congress 2025 and published in the New England Journal of Medicine Positive full results from the ​BaxHTN Phase III trial showed ​baxdrostat demonstrated a statistically significant and clinically meaningful reduction in mean seated systolic blood pressure (SBP) at two doses (2mg and 1mg) compared with placebo at 12 weeks. Results were seen in patients with hard-to-control (uncontrolled and resistant) hypertension who received baxdrostat or placebo on top

    8/30/25 10:19:00 AM ET
    $AZN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AIH
    $AZN
    $BLCT
    $BTCM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by 51Talk Online Education Group

    SC 13D/A - 51Talk Online Education Group (0001659494) (Subject)

    12/17/24 4:07:04 PM ET
    $COE
    Other Consumer Services
    Real Estate

    SEC Form SC 13D filed by Quhuo Limited

    SC 13D - QUHUO Ltd (0001781193) (Subject)

    10/15/24 7:19:18 PM ET
    $QH
    Real Estate

    SEC Form SC 13D filed by Quhuo Limited

    SC 13D - QUHUO Ltd (0001781193) (Subject)

    10/15/24 7:17:52 PM ET
    $QH
    Real Estate